Key facts
- This page summarizes William Strohl's Form 4 filing for IGM Biosciences, Inc. (IGMS).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 14 Mar 2024, 17:57.
William Strohl - 12 Mar 2024 Form 4 Insider Report for IGM Biosciences, Inc. (IGMS)
- Reporting relationship
- Director
- Issuer ticker
- IGMS
- Reported as of
- 12 Mar 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 14 Mar 2024, 17:57:27 UTC
- Prior SEC filing
- 06 Apr 2023
- Next SEC filing
- 12 Aug 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Misbah Tahir, by power of attorney
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
William Strohl filed Form 4 for IGM Biosciences, Inc. (IGMS) on 14 Mar 2024.
Change
- Previous filing in this sequence was filed on 06 Apr 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
IGMS
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +29,400
- Change %
- Price
- $0.000000
- Shares after
- 29,400
- Date
- 12 Mar 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 29,400
- Exercise price
- $9.95
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
1/12 of the shares subject to the option shall vest each month following the Issuer's 2024 Annual Meeting of Stockholders on the same day of the month, subject to Reporting Person remaining a Service Provider through each such date. Notwithstanding the foregoing, the shares subject to the option will be fully vested no later than the date of the Issuer's 2025 Annual Meeting of Stockholders.